Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN) (PIN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01788332

Recruitment Status : Unknown

Verified October 2018 by Lisette Nixon, Velindre NHS Trust.
Recruitment status was: Active, not recruiting

First Posted : February 11, 2013

Last Update Posted : October 26, 2018

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

AstraZeneca

Information provided by (Responsible Party):

Lisette Nixon, Velindre NHS Trust

Results Submitted - Not Posted on ClinicalTrials.gov

Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

Recruitment Status :	Unknown
Estimated Primary Completion Date :	December 2018
Estimated Study Completion Date :	December 2018

Submission Cycle	Results Submitted to ClinicalTrials.gov	Results Returned after Quality Control Review
1	June 17, 2021	July 9, 2021

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Fennell DA, Porter C, Lester J, Danson S, Blackhall F, Nicolson M, Nixon L, Gardner G, White A, Griffiths G, Casbard A. Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial. EClinicalMedicine. 2022 Aug 11;52:101595. doi: 10.1016/j.eclinm.2022.101595. eCollection 2022 Oct.

To Top